Activity Description and Educational Objectives

In this activity, a renowned expert in asthma discusses the role of targeted treatment in the management of patients with severe asthma.

Upon completion of this activity, participants should be better able to:

• Discuss the pathogenesis of severe asthma in the context of features that represent targets for novel biologic therapies
• Identify targeted biologic treatments for severe asthma in terms of their mechanism of action, efficacy, and safety
• Employ strategies to phenotype patients with severe asthma in order to select the most appropriate treatment
• Apply approaches to communicate with severe asthma patients regarding unique aspects of their disease and the management plan

Target Audience

This activity has been designed to meet the educational needs of allergists, immunologists, pulmonologists, internal medicine physicians, and other clinicians involved in the treatment of patients with asthma.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: October 13, 2017 - October 12, 2018
Time to Complete: 60 minutes

Faculty & Disclosure / Conflict of Interest Policy

In accordance with ACCME requirements, Penn State College of Medicine has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.

Course Director

Eugene R. Bleecker, MD
Co-Director of the Division of Pharmacogenomics
Co-Chief, Division of Genetics, Genomics and Precision Medicine
The University of Arizona Health Sciences
Tucson, Arizona

Eugene R. Bleecker, MD, has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from AsthmaNET; National Institutes of Health (NIH); Pharmacogenetics; SARP Pharmaceuticals PVT. LTD; and Spiromics. AstraZeneca-MedImmune; Boehringer Ingelheim Pharmaceuticals, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd; GlaxoSmithKline; Johnson & Johnson Services, Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; sanofi-aventis/Regeneron Pharmaceuticals, Inc.; and Teva Pharmaceuticals for clinical trials administered through Wake Forest School of Medicine and/or the University of Arizona.
Speakers Bureau participant with AstraZeneca-MedImmune; Boehringer Ingelheim Pharmaceuticals, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd; GlaxoSmithKline; Knopp Biosciences LLC; Novartis Pharmaceuticals Corporation; sanofi-aventis/Regeneron Pharmaceuticals, Inc.; and Vectura Group plc.

Medical Director

Kate Nelson, PhD
PVI, PeerView Institute for Medical Education

Kate Nelson, PhD, has no financial interests/relationships or affiliations in relation to this activity.

Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.

Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.

Providership, Credit & Support

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine and PVI, PeerView Institute for Medical Education. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The Penn State College of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Information about CME credit for this activity is available by contacting Penn State at 717-531-6483 or ContinuingEd@hmc.psu.edu. Reference course # G6168-18-T.

Providership

This CME activity is jointly provided by Penn State College of Medicine and PVI, PeerView Institute for Medical Education.

Support

This educational activity is supported by an educational grant from GlaxoSmithKline.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.

Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView Press or any of its partners, providers, and/or supporters.

Copyright © 2000-2017, PeerView Press